3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
7
Endocrine
7
Thoracic
5
Gastrointestinal
5
CNS
4
Breast
3
Sarcoma
2
Gynecologic
2
Dermatologic
2
Other solid neoplasm
1
NET
1
Genitourinary
1
Conditions
Neuroendocrine Tumors
43
Carcinoma, Neuroendocrine
8
Gastro-enteropancreatic neuroendocrine tumor
7
Sarcoma
6
Carcinoid Tumor
6
Stomach Neoplasms
5
Small Cell Lung Carcinoma
5
Paraganglioma
5
Neoplasms
5
Prostatic Neoplasms
4
Pheochromocytoma
4
Neoplasm Metastasis
4
Lung Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma
4
Thyroid Neoplasms
3
Neuroblastoma
3
Carcinoma, Renal Cell
3
Thyroid Diseases
2
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Ovarian Neoplasms
2
Neuroectodermal Tumors
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Meningioma
2
Medulloblastoma
2
Interventions
pralsetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Thyroid Cancer, Papillary
×
NET
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA